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ABSTRACT 
Introduction/objectives:  Whilst analgesics and medications have demonstrated efficacy for people 
with osteoarthritis, their effectiveness is dependent on adherence. This has previously been reported as 
particularly low in this population. The purpose of this meta-ethnography was to explore possible 
perceptions for this. 
Method: A systematic review of published and unpublished literature was undertaken. All qualitative 
studies assessing the attitudes or perceptions of people with osteoarthritis towards medication 
adherence were eligible. Study quality was assessed using the Critical Appraisal Skills Programme 
Qualitative tool. Analysis was undertaken using a meta-ethnography approach, distilling to a third 
order construct and developing a line of argument. 
Results: From 881 citations, five studies met the eligibility criteria. The meta-ethnography generated a 
model where medication adherence for people with osteoarthritis is perceived as a balance between 
the willingness or preference to take medications with the alterative being toleration of symptoms. 
Motivators to influence this ‘balance’ may fluctuate and change over time but include: severity of 
symptoms, education and understanding of osteoarthritis and current medications, or general health 
which may raise issues for poly-pharmacy as other medications are added or substituted into the 
patient’s formulary. 
Conclusions: Medicine adherence in people with osteoarthritis is complex, involving motivators 
which will fluctuate in impact on individuals at different points along the disease progression. 
Awareness of each motivator may better inform clinicians as to what education, support or change in 
prescription practice should be adopted to ensure that medicine adherence is individualised to better 
promote long-term behaviour change. 
Keywords: drug; compliance; systematic review; musculoskeletal; elderly 
PROSPERO Registration Number: CRD42014013594 
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INTRODUCTION 
Osteoarthritis is a painful and debilitating chronic musculoskeletal disease which most commonly 
affects older people, impacting on their lifestyles, functional independence and quality of life [1,2]. 
The most common joints affected by osteoarthritis include the carpometacarpal, knee, hip and spine 
[3]. It is projected that the number of people with osteoarthritis will increase to nearly 67 million by 
2030 in the United States of America alone [4,5]. With an ageing population, this will pose a major 
social and healthcare burden on already stretched primary and secondary care settings [6]. 
The NICE guidelines [7] and similar international recommendations have placed medications such as 
paracetamol, codeine and NSAIDs as frontline treatments for this population [7,8,9]. Whilst these 
have clearly demonstrated efficacy for people with osteoarthritis, such treatments are only effective 
whilst people comply with prescriptions [7,10]. Treatment adherence has been acknowledged as a 
major problem within this population in relation to exercise, weight-management and medication 
[10,11]. Whilst cited as a problem, little evidence has been undertaken to explore why medication 
adherence is a particular problem for people with osteoarthritis.  With better understanding on the 
reasons why people do not adhere to their medications, it may be possible to develop strategies to 
counter these reasons and perceptions. If successful, the efficacy data on medications may be more 
likely to transfer into clinical outcomes, resulting in greater patient wellbeing, but also capability to 
self-manage symptoms, reducing burden on healthcare services. 
Given this rationale, the purpose of this review was therefore to examine the perceptions of people 
with osteoarthritis to medications to better understand why people take or do not take medications for 
symptom control.  
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MATERIALS AND METHODS 
This systematic review was undertaken within the Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) [12] statement.  
 
Search Strategy 
 
The primary search was undertaken of the published literature databases: AMED, EMBASE, 
MEDLINE, PsycINFO, BNI, CINAHL, the Cochrane library on 10th November 2015. The secondary 
search included the grey literature and trial registries: OpenGrey (System for Information on Grey 
Literature in Europe), WHO International Clinical Trials Registry Platform, Current Controlled Trials 
and the United States National Institute of Health Trials Registry). All searches were undertaken from 
database inception to Week 2 November 2015. An example of the MEDLINE search strategy is 
presented in Table 1. The basis of this was modified for the other search strategies. 
 
All reference lists of included papers and relevant review papers were screened to identify potentially 
omitted articles.  All corresponding authors were contacted by email to determine whether any 
currently unpublished or previously unidentified papers could be identified for the final review. 
 
Eligibility Criteria 
Studies were included if they:  
 
(a) examined patient perceptions of medication and drug adherence or compliance. We assessed 
compliance for any medication including analgesics, anti-depressives or anti-psychotics for example, 
but only for people with osteoarthritis.  
 
(b) recruited people with osteoarthritis (irrespective of body region). Diagnosis of osteoarthritis was 
defined by the American College of Rheumatology (ACR) criteria for diagnosing osteoarthritis [13]. 
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Participants described as having  experienced knee pain for more than 25 of the last 30 days, and 
experienced morning stiffness of less than 30 minutes in duration were also included if a specific 
documentation of ACR criteria was not provided.  
 
(c) qualitative or survey design studies. We did not place a restriction on the language of paper or date 
of publication.  
 
Two reviewers (TD, TS) independently reviewed the titles and abstracts from all potentially relevant 
papers using the pre-defined eligibility criteria. Full texts of all potentially eligible papers were 
reviewed by the two reviewers before making a final decision on eligibility. Studies that did not 
satisfy the eligibility criteria were excluded. Any disagreement between the reviewers on paper 
eligibility was resolved through discussion. 
 
Data Extraction 
 
One reviewer (TD) independently extracted all data onto a pre-defined data extraction table. This was 
verified by a second reviewer (TS). Data extracted included: the number of participants; age of 
participants; gender mix of cohort; duration of osteoarthritis; presence of multi-joint osteoarthritis; 
presence and type of co-morbidities; perceptions, attitudes, experiences, views of people towards 
medication adherence and compliance. Any disagreements in data extraction between the two 
reviewers were resolved through discussion. 
 
Outcome Measures 
 
The primary outcome measurement was patient experience of medication adherence and the barriers 
and facilitators reported by participants. 
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Quality Assessment 
We critically appraised each included paper using the Critical Appraisal Skills Programme (CASP) 
qualitative appraisal tool [14]. Two additional criteria were incorporated to the CASP assessment 
which were deemed important for this specific research question. We assessed whether the sampling 
frame provided variability for: (1) degree of pain; (2) medication adherence/non-adherence. This was 
felt important given the research question and requirement to gain a representation of the 
osteoarthritis population on two ‘moderators’ which may have directly influenced perception of 
medication adherence. One reviewer (TD) independently appraised each paper. This was verified by a 
second reviewer (TS). If disagreements arose in critical appraisal assessment, this was resolved 
through discussion between the two reviewers. 
 
Data Synthesis 
The qualitative study data were synthesised using a meta-ethnography approach. Through this, 
following data emersion, emerging themes were identified to examine how concepts juxtaposed or 
related to one another [15]. Relevant themes were grouped into categories by two reviewers 
independently (TD, TS). Categories were created on the basis of primary data from the included 
studies rather than prior knowledge [15]. Constant comparative techniques were then used to compare 
how emergent categories related to the primary data/original texts. The results were compared 
between each reviewer and consensus was reached through discussion to identify all agreed primary 
and secondary-order themes. Analysis of these key categories was then undertaken through the 
reciprocal translation, refurerational analysis and development of lines of argument to gain a third-
order construct [15,16].  
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RESULTS 
Search Results 
The results of the search strategy are presented in Figure 1. A total of 881 citations were identified 
from the search strategy when duplicates were removed. After full-texts were reviewed, 76 papers 
were deemed potentially relevant. Following re-assessment, five satisfied the eligibility criteria and 
were included. 
Quality Assessment 
The results of the critical appraisal are presented in Table 2. As this illustrates, three of the five 
studies presented with high quality, two presented as low quality. Recurrent limitations across the 
evidence-base included not explicitly relating the results into clinical practice to facilitate the 
transferability of the results in four studies [17,18,19,20]. Only two studies clearly explored the 
relationship between the researcher and participant and considered the impact of these on their 
findings [17,20]. Both Milder et al [18] and Sale et al [19] documented their data collection processes 
clearly, but neither clearly documented and presented their data analysis approaches clearly. However, 
recurrent strengths illustrated in all studies included clarity in the research question and design 
adopted, a clearly documented recruitment strategy, a clear statement of findings, and recruited people 
with a varied level of pain and medication adherence levels, to explore a variety of attitudes and 
perceptions on this topic. 
Characteristics of Included Studies 
The characteristics of the included studies are presented in Table 3. Of the five included studies, three 
were semi-structured interviews [18,19,21], two were survey study designs [17,20]. Two studies were 
undertaken in Australia [17,18], one in Canada [19], one in France [21], whilst Blamey et al’s [20] 
study was undertaken in the UK. 
A total of 519 participants were included in the analysis. This included 404 participants from the two 
survey studies [17,20], and 115 participants who were sampled for the three semi-structured interview 
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studies [18,19,21]. There were largely equal proportions of males and females represented in each 
study, with the exception being Alami et al [21] where 73% of the cohort were female, and Blamey et 
al [20] where 71% were female. Mean age of the cohorts ranged from 55 years [20] to 62 years [17]. 
All studies recruited independent community dwelling subjects rather than institutional care home 
residents. Whilst neither Milder et al [18] nor Blamey et al [20] signified the proportionality of the 
specific joints affected by osteoarthritis, this was documented in three papers. Participants in Laba et 
al [17] and Alami et al [21] presented with solely knee osteoarthritis whilst Sale et al’s [19] cohort 
presented with hip and/or knee osteoarthritis. The co-morbidities presented in each cohort were 
documents in three studies [17,18,19]. In these studies, a significant proportion presented with at least 
one co-morbidity, 93% in Milder et al’s [18] case. The most common co-morbidities were 
hypertension and heart conditions (52%)[17], and diabetes mellitus (over 50%)[19]. 
Meta-Ethnography 
Four themes emerged. These included: severity of symptoms; perceived effectiveness of medication; 
side effects and acceptability; and knowledge and education. 
Severity of symptoms 
Three factors were perceived as important moderators to medication adherence for people with 
osteoarthritis related to severity of pain. The level of pain experienced by the patient was regarded as 
an important variable to adherence. People who reported greater pain felt more likely to adhere to 
their prescribed analgesic regime rather than those who experienced less pain [19,20]. Furthermore 
those who experienced greater pain levels also reported taking their analgesics pre-emptively rather 
than as-and-when required [19]. The severity but also impact of pain on individual’s lifestyles and 
sleeping patterns were also perceived as important factors in medication adherence [19]. This 
distinction in symptom severity and frequency was made in patients through those who used 
analgesics to manage occasional flares in symptoms (non-adherence, self-managing their medications) 
as opposed to those who experienced recurrent or daily symptoms who were more likely to use 
symptoms as their guide to administration [19]. 
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Perceived effectiveness of medication 
A recurrent factor which impacted on adherence was the patient experience regarding the 
effectiveness of the medication. Sale et al [19], Milder et al [18] and Laba et al [17] reported that 
people with osteoarthritis were more adherent to their medications if they felt that the medication 
would relieve pain sufficiently over and above potential negative side effects. This ‘balance’ between 
the pros-and-cons of taking medications was seen as critical in decision-making for this population, 
and emphasised the need for clarity and education on medications.  
The issue of effectiveness was also related to the mode of action. Laba et al [17] reported that people 
who were prescribed a slow-acting, disease-modifying medications such as glucosamine or cod liver 
oil were more adherent as opposed to fast-acting, immediate pain relief provided with NSAIDs. This 
was hypothesised to be related to the side-effects of NSAIDs over disease-modifying drugs, but it 
remains unclear whether this is the case or whether it can be attributed to a preference to these 
medication types [17]. 
Side effects and acceptability  
In relation to the balance between ‘pros-and-cons’ for regularly taking medications, the major 
disincentive remains side-effects and how taking medications can be effectively implemented within 
people’s lifestyles with least inconvenience or complications. Fear related to side-effects were 
reported in four studies [17,18,19,21]. Side-effects were defined as either providing minor effects 
such as constipation or doziness [17,18,19], or more serious, long-term effects such as stomach ulcers 
or addiction [17,18,19,21]. The principle concern surrounded NSAIDs and long-term usage was 
gastric complications. However, Alami et al [21] and Sale et al [19] emphasised a fear regarding 
addiction with this being an overwhelming side-effect influencing individual’s medication adherence. 
This was firstly related to a fear that with continued use, individuals could not ‘manage’ without 
analgesics, with a fear of dependency and loss of control without medications [19]. Secondly, Alami 
et al [21] acknowledged participant’s fears that analgesics, morphine in this instance, may ‘mask’ 
symptoms and therefore provide a confusion as to being able to detect pain or not, and the paradox 
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that if they take their medications, they may not be able to acknowledge they are suffering and 
therefore, for some reason, feel fraudulent in attending routine medical reviews for osteoarthritis. In 
this way, there may be a suggestion that some people still wished to feel that they are in some 
suffering to be able to identify themselves as someone with osteoarthritis rather than someone who 
takes medication to mask symptoms.  
The acceptability and inconvenience of specific dose regimes were identified as detrimental effects 
which impacted on medication adherence. Laba et al [17] and Milder et al [18] reflected findings that 
daily, more formulaic, ‘pill-loading’ prescriptions posed greater problems in adherence. Conversely, 
Alami et al [21] reported greater support and adherence towards topical treatments such as Diclofenac 
cream being led and administered locally which were perceived as more ‘understandable’ in mode of 
action than oral analgesic alternatives.  
Only Laba et al [17] reported medication adherence was influenced by out-of-pocket costs in their 
study from Australia. 
Knowledge and Education  
Issues surrounding knowledge and education arose around: practical support and education on how to 
and when to take medications; on the benefits and rationale for taking medications; and the impact of 
education and knowledge on participant’s self-efficacy towards their medication regime. 
Recurrently respondents cited limited knowledge and support on practical aspects of their medication 
regime. By being unclear on factors such as timing, dose and frequency of medications, over what 
time-scales, respondents reported being disillusioned and limited in motivation to adhere to their 
recommended regimes [17,18,19]. This was compounded through limited support and follow-up 
guidance from medical services [21]. Similarly both Sale et al [19] and Alami et al [21] reported the 
belief that the trivialising of osteoarthritis by healthcare professions, instilled a similar perception of 
the disease in individuals. This consequently had a negative impact on people’s desire to follow an 
analgesic regime. However, in instances where patients felt involved and incorporated in decision-
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making on medication regime, and felt listened to and invested within, medication adherence was 
reported as greater [21]. 
Finally, participant’s self-efficacy and locus of control over their disease and self-management was 
reported to pose a significant impact on medication adherence [17,20].  
Line of Argument 
The line of argument for these four themes created a new interpretation comprising one component 
with four inter-relating moderators. This is presented in Figure 2’s schema. At the core of medication 
adherence for people with osteoarthritis is the balance between the willingness or preference to take 
medications with the alterative being toleration of symptoms. This is dependent on multiple factors 
being: the effectiveness of medication, severity of side-effects, severity of symptoms and 
effectiveness of the medication. These all inter-relate and the loading or weight of these symptoms 
may fluctuate at different times for individuals dependent on status of current symptoms, education 
and understanding of the osteoarthritis and current medications or general health which may raise 
issues for poly-pharmacy as other medications are added or substituted into the patient’s 
pharmacological requirements. 
 
 
12 
 
DISCUSSION 
The findings of this meta-ethnography suggest that medication adherence for people with 
osteoarthritis is multi-factorial, with different ‘moderators’ being more significant at different times. It 
also suggests that people with osteoarthritis may have specific reasons for poor medication adherence 
compared to other medication conditions, related to health beliefs and perceptions surrounding 
osteoarthritis as a disease process. Now identified, these ‘moderators’ to medication adherence may 
be considered to individually tailor medication adherence to improve behaviour change for specific 
subgroups of the osteoarthritis population. These findings are largely based on a high quality 
evidence-base. However, given that three studies did not clearly state the relationship between the 
participants and researchers [18,19,21], it is not possible to ascertain whether this had an impact on 
the findings through social desirability bias. 
A key finding was the variability in factors perceived by people with osteoarthritis as moderators to 
adherence. This reflects differing characteristics within responders purposively sampled to gain such 
variability. Factors such as severity of symptoms, duration since diagnosis, gender and country of 
origin were all variables which were assessed in this study. This reiterates the requirement not to 
consider the osteoarthritis population as a homogenous group, i.e. not people with knee osteoarthritis, 
but people presenting with differing health beliefs, different levels of education and understanding of 
their condition and medication regimes, with different symptoms, with different expectations of their 
symptom management and physical requirements. Through this understanding of various strategies 
must be tailored and individualised to have a meaningful impact on medication adherence. Such a 
recommendation has been seen within the medication adherence literature in hypertension [22], 
asthma [23] and depression [24]. However, this understanding is particularly valid in the osteoarthritis 
population given the acknowledged variability in health beliefs regarding the condition itself, 
irrespective of beliefs surrounding pharmacological management [25]. Future interventions therefore 
should consider the individualisation of behaviour change, adopting models such as the social 
ecological model, to provide a theoretical underpinning for long-term behaviour change promoting 
medicine adherence.  
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The individualisation of medication adherence may also be related at a pathological level. It is 
acknowledged that not all people with osteoarthritis have the same pathological mechanism. Two 
broad groups have been hypothetised as the inflammatory-type and the mechanical non-inflammatory 
type osteoarthritis [26]. It is suggested that medications such as NSAIDs may be most effective for 
inflammatory-type patients, particularly in providing immediate pain relief. However, this meta-
ethnography repeatedly acknowledged a particular challenges with NSAID adherence, attributed to 
higher perceived side-effects. Given that the ‘balance’ as represented in Figure 2 related to perceived 
benefit over risk, it may be suggested that consideration of side-effects over lower efficacy for the 
mechanical subgroup may dissuade physicians prescribing NSAID for this specific subgroup of the 
osteoarthritis population as this would have a potential impact on adherence. However identifying the 
specific phenotypes to determine this subgroup is still developing and therefore, until this is a widely 
acknowledged practice, such sub-grouping is not feasible.  
As suggested, medication adherence may differ across the osteoarthritis population. There is an 
understanding that osteoarthritis may be ‘just ageing’ rather than ‘medicalising’ the condition [25]. 
The realisation that osteoarthritis is not currently curative, and that medications for symptom 
management are long-term can have a negative impact, particularly on the fear of additional and 
longer-term usage. Addressing this health belief, not only in the individual, but also by supporting and 
educating patient’s family members or carers may be important as they have an integral part in 
medication adherence, particularly in those with greater physical and cognitive care needs. 
Secondly, compared to medications for other conditions, such as hypertension, Sale et al [19] reported 
respondents were more comfortable modifying analgesic regimes. This may be attributed to their 
perception of osteoarthritis as a less life-threatening condition. This issues may require further 
consideration when counselling patients on both the pathophysiology of osteoarthritis and how 
medications can alter this through a therapeutic-ladder. Such an analogy may have a significant 
impact on this moderator in medication adherence for people with osteoarthritis.  
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A significant limitation posed by the current evidence-base related to sampling bias. As demonstrated 
in Table 3, the populations largely recruited younger/middle aged participants, with the oldest mean 
age being 62 years [17]. Accordingly, this paper provides valuable insights into  medication 
adherence in younger patients and those newly-diagnosed with osteoarthritis. However, it is not 
possible to make comment on medication adherence challenges in older people. This is important for 
a number of reasons. Firstly, with an ageing population expected to present with a greater prevalence 
of osteoarthritis, medication management in this population should be considered as it will pose an 
increasing burden on health and social care [5]. Secondly, this population present with unique medical 
complications which could impact on their capacity to adhere to medication regimes. These are 
largely around cognitive impairment with declining cognitive function and short-term memory, in 
addition to multiple co-morbidities such as cardiac, respiratory and gastrointestinal pathologies. 
Notably the five included studies poorly reported the presence of comorbidities. Accordingly it was 
not possible to evaluate what affect this may have made on medication adherence. Nonetheless, such 
comorbidities could theoretically preclude certain medications from being prescribed or alter the 
mode of delivery, in addition to presenting with further barriers through the increased risk of drug 
interactions with poly-pharmacy. Based on these reasons, further investigation should be a research 
priority to identify the specific medical adherence challenges faced by older people and those with a 
variety of comorbidities. Furthermore research is warranted to seek the views of this group of 
patient’s families and carers in domestic dwellings or care institutions as these may also provide 
valuable perspectives of wider mechanisms which may impact on medication adherence.  
 
Whilst the findings of this meta-ethnography have allowed a comparison on the beliefs and 
experiences of medication adherence for people with osteoarthritis across four different countries, 
there appeared limited variation in these between participants from Australia [17,18], Canada [19], 
France [21] and the UK [20]. This may be attributed to a ‘real’ limited variability in beliefs between 
people from these countries. Alternatively specific differences in cultural background, health 
psychology, pain perception and self-management may not have been specifically explored which 
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may truly exist. Further study to compare differences across these countries for these factors would 
clarify this. Furthermore, differences in perceptions across other cultures, particularly in Asia and 
Africa, may be beneficial to ascertain how different health systems and populations’ cultural 
backgrounds may provide different insights to those previously reported for medication adherence. 
 
CONCLUSIONS 
Medication adherence is a complex problem for people with osteoarthritis, with a number of different 
‘moderators’ which impact on adherence at different times. Adherence is perceived as a balance 
between willingness or preference to take medications as considered beneficial and effective, with the 
alterative being toleration of symptoms in the face of negatively perceived factors such as severity of 
side-effects, severity of symptoms, acceptability of dosing regimes, and overall health beliefs around 
osteoarthritis. Further study remains to explore whether this adherence such as cognitive impairment, 
and other medical co-morbidities which could impact on adherence in alternative ways than 
previously understood. 
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Figure 1: PRISMA Flow-Chart depicting the search strategy results 
 
Records identified through database 
searching 
(n =881) 
S
cr
e
e
n
in
g
 
In
cl
u
d
e
d
 
E
li
g
ib
il
it
y
 
Id
e
n
ti
fi
ca
ti
o
n
 
Additional records identified through 
other sources 
(n = 0) 
Records after duplicates removed 
(n =  687) 
Records screened 
(n = 687) 
Records excluded 
(n = 611) 
Full-text articles assessed for eligibility 
(n = 76) 
Full-text articles excluded, 
with reasons 
(n = 71) 
Did not assess adherence 
(56) 
Population not OA (7) 
Review paper (4) 
RCTs (4) 
Studies included in qualitative synthesis 
(n = 5) 
Studies included in quantitative synthesis (meta-analysis) 
(n = 0) 
22 
 
Figure 2: Schema of the line of argument generated from the four themes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Theme 4 
 
• Perceived use of medication for flares or 
prophylactic. 
• Education/knowledge on require medication 
regime. 
• Perception of osteoarthritis as a disease-process 
vs. ageing. 
• Perceived patient role in decision-making on 
medication regime. 
 
    Adherent 
              Non-Adherent 
Theme 1 
 
• Severity of osteoarthritis symptoms. 
• Impact on lifestyle and frequency of symptoms. 
 
Theme 2 
 
• Perceived effectiveness of medicine. 
 
Theme 3 
 
• Severity and frequency of side-effects. 
• Acceptability and convenience of prescribed 
regime. 
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Table 1: MEDLINE search strategy 
 
 
 
 
 
 
. 
 
 
 
 
 
 
1. Medication 
2. Drug 
3. Analgesics 
4. Pharmacological 
5. OR/1-4 
6. Adherence 
7. Compliance 
8. Concordance 
9. OR/6-8 
10. Musculoskeletal pain 
11. Joint pain 
12. Osteoarthritis 
13. Arthritis 
14. Arthropath$ 
15. OR/10-14 
16. AND/5,9,15 
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Table 2: Critical Appraisal – CASP Qualitative Critical Appraisal Tool (modified) 
 
Criterion 
A
la
m
i 
e
t 
a
l 
[2
1
] 
B
la
m
e
y
 e
t 
a
l 
[2
0
] 
L
a
b
a
 e
t 
a
l 
[1
7
] 
M
il
d
e
r 
e
t 
a
l 
[1
8
] 
S
a
le
 e
t 
a
l 
[1
9
] 
Was there a clear statement of the aims of the research?      
Is a qualitative methodology appropriate?      
Was the research design appropriate to address the aims of the 
research? 
     
Was the recruitment strategy appropriate to the aims of the 
research? 
     
Were the data collected in a way that addressed the research 
issue? 
   x x 
Has the relationship between researcher and participants been 
adequately considered? 
x   x x 
Have ethical issues been taken into consideration?   x   
Was the data analysis sufficiently rigorous?    x x 
Is there a clear statement of findings?      
Is the research valuable to clinical practice? 
 
 x x x x 
Sample stratification by degree of pain      
Medication adherence stratified by pain      
Overall Methodological Quality H H H L L 
H – High Risk of Bias; L – Low Risk of Bias; U - Unclear
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Table 3: Included Study Characteristics Table 
Study Study Design Study 
country of 
origin 
Sample 
Size 
Gender 
(m/f 
%) 
Age in years 
(mean or 
range or 
both) 
Place of residence 
(Community vs. care 
home)  
OA Joint 
Affected 
Co-morbidities 
Alami et al 
[21] 
Semi-
structured 
interviews 
France 81 27/73 >44 Community Knee N/S 
Blamey et al 
[20] 
Survey UK 216 29/71 55 (SD 14.8) Community N/S N/S 
Laba et al 
[17] 
Survey Australia 188 48/52 62 (SD 8.5) Community Knee Hypertension/Heart 
(52%); 
Ulcer/Stomach 
(7.5%) 
Milder et al 
[18] 
Semi-
structured 
interviews 
Australia 15 47/53 >64 Community N/S All co-morbidities 
93% 
Sale et al [19] Semi-
structured 
interviews 
Canada 19 47/53 <66 (67-82) Community Hip and Knee >50% diabetes 
F – females; M – males; N/S – Not stated; OA – osteoarthritis;  SD – standard deviation; UK – United Kingdom 
 
 
 
 
 
 
 
